CD80 and neoplasm: The analysis of the immunological events occurring early after the inflammatory insult in our model of CRC revealed that CD80-CD28 signaling pathway blockade results in inadequate lymphocytes activation that might induce antigen-specific tolerance and tumor progression [36].